<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375440</url>
  </required_header>
  <id_info>
    <org_study_id>L05-063</org_study_id>
    <nct_id>NCT00375440</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Study</brief_title>
  <official_title>Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if tranexamic acid significantly reduces blood loss
      and blood transfusion in revision total hip replacement. Tranexamic acid is a drug that helps
      to reduce blood loss during surgery. Revision total hip replacement surgery is treatment for
      patients who have previously had hipe replacement surgery which failed and must be
      repaired/replaced.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid is an anti-fibrinolytic agent that inhibits fibrinolysis leading to a
      reduction of blood loss without concurrently increasing the risk of thromboembolic
      complications. Several studies have shown that tranexamic acid reduces blood loss and blood
      transfusions in primary total hip and knee arthroplasty. However, there have not been any
      studies that evaluate its efficacy in revision total hip arthroplasty. The significance of
      this study is that the need for blood transfusions and their complications may be minimized
      in revision hip arthroplasty if tranexamic acid is found to significantly decrease the amount
      of blood transfusions.

      After the patient has been consented, he or she will be randomized into one of two groups
      (tranexamic acid and placebo) by the School of Pharmacy. The placebo will be crystalloid
      fluid of equal volume as tranexamic acid. The patient will then undergo revision total hip
      arthroplasty by Dr. Rosenstein and be administered tranexamic acid or placebo. Blood loss
      will be recorded intraoperatively and postoperatively through drains. Criteria for blood
      transfusion include hemoglobin less than 10g/dl or hematocrit less than 30%. Once the
      operation ends, the drug or placebo will be discontinued and the postoperative care is
      unchanged from current standards/protocols. Intraoperative blood loss, total blood loss, and
      number of blood transfusions will be recorded and analyzed. Length of acute hospital stay
      will also be recorded. A cost analysis will be performed comparing tranexamic acid to blood
      transfusions.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study halted prematurely as investigator left the institution.
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Introperative blood loss</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Total blood loss</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of blood transfusions required</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of acute hospital stay</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Failed primary total hip arthroplasty (femoral stem, acetabular component, or both)

          -  18-100 years of age

        Exclusion Criteria:

          -  Prosthetic infection

          -  Primary total hip arthroplasty

          -  Prisoners

          -  Pregnancy

          -  Previous adverse reaction to tranexamic acid

          -  Bleeding/coagulation disorders

          -  Renal insufficiency (serum creatinine&gt;two standard deviations for age)

          -  History of deep venous thrombosis or pulmonary embolism

          -  Religious beliefs/practices prohibiting blood transfusions

          -  Wards of the state

          -  Cognitively impaired patients

          -  Terminally ill patients

          -  Students and/or employees

          -  Color blindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander D Rosenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center Department of Orthopaedic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center Department of Orthopaedic Surgery</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000 Jun;71(3):250-4.</citation>
    <PMID>10919295</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand. 2001 Oct;72(5):442-8.</citation>
    <PMID>11728069</PMID>
  </reference>
  <reference>
    <citation>D'Ambrosio A, Borghi B, Damato A, D'Amato G, Antonacci D, Valeri F. Reducing perioperative blood loss in patients undergoing total hip arthroplasty. Int J Artif Organs. 1999 Jan;22(1):47-51.</citation>
    <PMID>10098585</PMID>
  </reference>
  <reference>
    <citation>Ekbäck G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckström J, Carlsson O, Schött U. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg. 2000 Nov;91(5):1124-30.</citation>
    <PMID>11049894</PMID>
  </reference>
  <reference>
    <citation>Garneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. J Arthroplasty. 2004 Jun;19(4):488-92.</citation>
    <PMID>15188109</PMID>
  </reference>
  <reference>
    <citation>Hayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth. 1996 Aug;8(5):357-60.</citation>
    <PMID>8832445</PMID>
  </reference>
  <reference>
    <citation>Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemelä HM, Mäntylä SK, Kuisma RP, Ylinen JE. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg. 1997 Apr;84(4):839-44.</citation>
    <PMID>9085968</PMID>
  </reference>
  <reference>
    <citation>Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003 Oct;31(5):529-37.</citation>
    <PMID>14601276</PMID>
  </reference>
  <reference>
    <citation>Husted H, Blønd L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand. 2003 Dec;74(6):665-9.</citation>
    <PMID>14763696</PMID>
  </reference>
  <reference>
    <citation>Ido K, Neo M, Asada Y, Kondo K, Morita T, Sakamoto T, Hayashi R, Kuriyama S. Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg. 2000;120(9):518-20.</citation>
    <PMID>11011672</PMID>
  </reference>
  <reference>
    <citation>Janssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology. 1994 Jan;80(1):23-9.</citation>
    <PMID>7507304</PMID>
  </reference>
  <reference>
    <citation>Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R. Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study. J Bone Joint Surg Br. 2003 Mar;85(2):174-7.</citation>
    <PMID>12678347</PMID>
  </reference>
  <reference>
    <citation>Kasper SM, Elsner F, Hilgers D, Grond S, Rütt J. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol. 1998 Nov;15(6):669-75.</citation>
    <PMID>9884852</PMID>
  </reference>
  <reference>
    <citation>Langdown AJ, Field J, Grote J, Himayat H. Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty. 2000 Dec;15(8):1009-12.</citation>
    <PMID>11112196</PMID>
  </reference>
  <reference>
    <citation>Lemay E, Guay J, Côté C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. Can J Anaesth. 2004 Jan;51(1):31-7.</citation>
    <PMID>14709457</PMID>
  </reference>
  <reference>
    <citation>Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg. 1995 Feb;80(2):343-8.</citation>
    <PMID>7529467</PMID>
  </reference>
  <reference>
    <citation>Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000 May;82(5):675-84.</citation>
    <PMID>10819278</PMID>
  </reference>
  <reference>
    <citation>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br. 2001 Jul;83(5):702-5.</citation>
    <PMID>11476309</PMID>
  </reference>
  <reference>
    <citation>Walsh TS, McClelland DB. When should we transfuse critically ill and perioperative patients with known coronary artery disease? Br J Anaesth. 2003 Jun;90(6):719-22.</citation>
    <PMID>12765883</PMID>
  </reference>
  <reference>
    <citation>Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases. Int Orthop. 2004 Apr;28(2):69-73. Epub 2003 Oct 10.</citation>
    <PMID>15224162</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>October 2, 2015</last_update_submitted>
  <last_update_submitted_qc>October 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Alexander Rosenstein, MD</name_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Revision Total Hip Replacement</keyword>
  <keyword>Reduction in Blood Loss</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

